Lisata Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Lisata Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Lisata Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Lisata Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lisata Therapeutics Inc (Lisata Therapeutics) is a pharmaceutical research company that focuses on discovery, development, and commercialization of therapies for advanced solid tumors and other major diseases. The company-lead product certepetide (LSTA1) is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors. Lisata Therapeutics also developing pipelines for various indications such as first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), pancreatic, colon, and appendiceal cancers, cholangiocarcinoma, glioblastoma multiforme, locally advanced, non-resectable, gastroesophageal adenocarcinoma and others. The company utilizes its proprietary CD34+ cell therapy technology to develop therapies for ischemia diseases. It operates in Australia, Ireland, Japan, the UK and the US. Lisata Therapeutics is headquartered in Basking Ridge, New Jersey, the US.
Headquarters
United States of America
Address
Second Floor, 110 Allen Road, Basking Ridge, New Jersey, 07920
Website
www.lisata.com
Telephone
1 908 8420100
No of Employees
21
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LSTA (NASD)
Revenue (2025)
$170,000
-83%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
17%
(2025 vs 2024)
Market Cap*
$29.7M
Net Profit Margin (2025)
XYZ
-388.2%
(2025 vs 2024)
* As of and is in US$
Lisata Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | CendR |
| Certepetide (LSTA1): Advanced Solid Tumors | |
| Technology: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In January, the company signed a binding term sheet to be acquired by Kuva Labs Inc. |
| 2024 | Contracts/Agreements | In December, the company and Kuva Labs entered into a partnership to develop new magnetic resonance imaging agents for the early, non-invasive, and precise identification of solid tumors. |
| 2024 | Contracts/Agreements | In July, the company entered into a research partnership with Haystack Oncology to utilize the Haystack MRD Technology to evaluate efficacy of Pancreatic Cancer treatment. |
Competitor Comparison
| Key Parameters | Lisata Therapeutics Inc | Krystal Biotech Inc | Bio Green Med Solution Inc | BrainStorm Cell Therapeutics Inc | Capricor Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Malaysia | United States of America | United States of America |
| City | Basking Ridge | Pittsburgh | Kuala Lumpur | New York | San Diego |
| State/Province | New Jersey | Pennsylvania | Kuala Lumpur (Federal Territory of) | New York | California |
| No. of Employees | 21 | 295 | 12 | 27 | 231 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gregory B. Brown, M.D. | Chairman | Executive Board | 2016 | 71 |
| David J. Mazzo Phd | Chief Executive Officer; Director; President | Executive Board | 2017 | 68 |
| James Nisco | Chief Accounting Officer; Senior Vice President - Finance and Treasury | Senior Management | 2024 | 54 |
| Gregory S. Berkin | Data Protection Officer; Chief Information Officer | Senior Management | 2015 | - |
| Kristen K. Buck, M.D. | Chief Medical Officer; Executive Vice President - Research and Development | Senior Management | 2021 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer